• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

产碳青霉烯酶菌株中头孢他啶-阿维巴坦耐药的出现及碳青霉烯类药物敏感性的恢复：一例报告及文献综述

Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Carbapenemase-Producing : A Case Report and Review of Literature.

作者信息

Shields Ryan K, Nguyen M Hong, Press Ellen G, Chen Liang, Kreiswirth Barry N, Clancy Cornelius J

机构信息

Department of Medicine, University of Pittsburgh, Pennsylvania.

XDR Pathogen Laboratory, University of Pittsburgh Medical Center, Pennsylvania.

出版信息

Open Forum Infect Dis. 2017 Jul 1;4(3):ofx101. doi: 10.1093/ofid/ofx101. eCollection 2017 Summer.

DOI:10.1093/ofid/ofx101
PMID:28685153
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5493938/
Abstract

We used meropenem to successfully treat a patient with bacteremia due to ceftazidime-avibactam-resistant, meropenem- susceptible that carried mutant . Meropenem was bactericidal against ceftazidime-avibactam- resistant isolates in vitro. Nevertheless, the role of carbapenems in treating such infections remains uncertain, because meropenem resistance is selected readily during passage experiments.

摘要

我们使用美罗培南成功治疗了一名因对头孢他啶-阿维巴坦耐药但对美罗培南敏感且携带突变体而发生菌血症的患者。美罗培南在体外对头孢他啶-阿维巴坦耐药菌株具有杀菌作用。然而，碳青霉烯类药物在治疗此类感染中的作用仍不确定，因为在传代实验过程中美罗培南耐药性很容易被筛选出来。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1ed/5493938/2cfa1c4521a6/ofx10102.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1ed/5493938/a347afdb9236/ofx10101.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1ed/5493938/2cfa1c4521a6/ofx10102.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1ed/5493938/a347afdb9236/ofx10101.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1ed/5493938/2cfa1c4521a6/ofx10102.jpg

相似文献

1
Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Carbapenemase-Producing : A Case Report and Review of Literature.产碳青霉烯酶菌株中头孢他啶-阿维巴坦耐药的出现及碳青霉烯类药物敏感性的恢复：一例报告及文献综述
Open Forum Infect Dis. 2017 Jul 1;4(3):ofx101. doi: 10.1093/ofid/ofx101. eCollection 2017 Summer.
2
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.耐碳青霉烯类肺炎克雷伯菌感染治疗期间因质粒介导的突变导致头孢他啶-阿维巴坦耐药的出现
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02097-16. Print 2017 Mar.
3
Selection of Imipenem Resistance Among Ceftazidime-Avibactam-Resistant, Imipenem-Susceptible Isolate With KPC-33 Carbapenemase.携带KPC-33碳青霉烯酶的对头孢他啶-阿维巴坦耐药、对亚胺培南敏感的菌株中亚胺培南耐药性的选择
Front Microbiol. 2021 Sep 23;12:727946. doi: 10.3389/fmicb.2021.727946. eCollection 2021.
4
Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases.对头孢他啶-阿维巴坦耐药、美罗培南敏感且携带变异型KPC-3碳青霉烯酶的肺炎克雷伯菌分离株进行美罗培南耐药性筛选。
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.00079-17. Print 2017 May.
5
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
6
Meropenem/vaborbactam activity : a new option for carbapenemase (KPC)-producing treatment.美罗培南/法硼巴坦活性：产碳青霉烯酶（KPC）治疗的新选择。
Future Microbiol. 2021 Nov;16:1261-1266. doi: 10.2217/fmb-2021-0007. Epub 2021 Oct 22.
7
Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.产 KPC-23 肺炎克雷伯菌 ST258 临床分离株对头孢他啶-阿维巴坦耐药的基因组特征。
Clin Microbiol Infect. 2019 Jun;25(6):763.e5-763.e8. doi: 10.1016/j.cmi.2019.03.011. Epub 2019 Mar 28.
8
Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in -Harboring Klebsiella pneumoniae Sequence Type 307 Isolates.携带blaKPC-2 的肺炎克雷伯菌序列型 307 分离株通过不同的基因组适应性连续出现头孢他啶-阿维巴坦耐药性。
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02101-17. Print 2018 Mar.
9
Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.中国耐碳青霉烯类肺炎克雷伯菌中头孢他啶/阿维巴坦耐药的出现。
Clin Microbiol Infect. 2020 Jan;26(1):124.e1-124.e4. doi: 10.1016/j.cmi.2019.08.020. Epub 2019 Sep 5.
10
Use of carbapenems in the combined treatment of emerging ceftazidime/avibactam-resistant and carbapenem-susceptible KPC-producing Klebsiella pneumoniae infections: Report of a case and review of the literature.碳青霉烯类药物联合治疗新出现的头孢他啶/阿维巴坦耐药和碳青霉烯类敏感产 KPC 肺炎克雷伯菌感染的应用：1 例病例报告及文献复习。
J Glob Antimicrob Resist. 2020 Sep;22:9-12. doi: 10.1016/j.jgar.2019.11.007. Epub 2019 Nov 13.

引用本文的文献

1
Emergence of KPC-8-producing infection without prior exposure to ceftazidime/avibactam: the threat of infections by ceftazidime/avibactam-resistant KPC variants.在未预先接触头孢他啶/阿维巴坦的情况下出现产KPC-8感染：头孢他啶/阿维巴坦耐药KPC变体感染的威胁。
Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0149424. doi: 10.1128/aac.01494-24. Epub 2025 Apr 22.
2
A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria.头孢他啶/阿维巴坦联合其他抗菌药物对耐碳青霉烯革兰氏阴性菌体外抗菌活性的系统评价及单菌属水平的Meta分析
J Antimicrob Chemother. 2025 Feb 3;80(2):334-346. doi: 10.1093/jac/dkae451.
3

本文引用的文献

1
Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases.对头孢他啶-阿维巴坦耐药、美罗培南敏感且携带变异型KPC-3碳青霉烯酶的肺炎克雷伯菌分离株进行美罗培南耐药性筛选。
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.00079-17. Print 2017 May.
2
Mutations in That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases.赋予头孢他啶-阿维巴坦耐药性的突变编码新型KPC-3变体，其作为超广谱β-内酰胺酶发挥作用。
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02534-16. Print 2017 May.
3
Evolution of ceftazidime-avibactam resistance driven by mutations in double-copy to during treatment of ST11 carbapenem-resistant .治疗 ST11 碳青霉烯类耐药肠杆菌科细菌时，由于双拷贝到的突变导致头孢他啶-阿维巴坦耐药性的进化。
mSystems. 2024 Oct 22;9(10):e0072224. doi: 10.1128/msystems.00722-24. Epub 2024 Sep 17.
4
Detection of KPC-216, a Novel KPC-3 Variant, in a Clinical Isolate of ST101 Co-Resistant to Ceftazidime-Avibactam and Cefiderocol.在一株对头孢他啶-阿维巴坦和头孢地尔耐药的ST101临床分离株中检测到新型KPC-3变体KPC-216。
Antibiotics (Basel). 2024 May 29;13(6):507. doi: 10.3390/antibiotics13060507.
5
Comparative In Vitro Activity of Ceftazidime-Avibactam, Imipenem-Relebactam, and Meropenem-Vaborbactam against Carbapenem-Resistant Clinical Isolates of and .头孢他啶-阿维巴坦、亚胺培南-瑞来巴坦和美罗培南-瓦博巴坦对耐碳青霉烯类临床分离株的体外活性比较
Antibiotics (Basel). 2024 May 1;13(5):416. doi: 10.3390/antibiotics13050416.
6
In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis.头孢他啶-阿维巴坦体外模拟体内 KPC 突变：表型、机制、酶水解的遗传结构和动力学。
Emerg Microbes Infect. 2024 Dec;13(1):2356146. doi: 10.1080/22221751.2024.2356146. Epub 2024 Jun 4.
7
Emerging challenges in antimicrobial resistance: implications for pathogenic microorganisms, novel antibiotics, and their impact on sustainability.抗菌药物耐药性的新挑战：对病原微生物、新型抗生素及其对可持续性影响的意义。
Front Microbiol. 2024 Apr 29;15:1403168. doi: 10.3389/fmicb.2024.1403168. eCollection 2024.
8
Candent issues in pneumonia. Reflections from the Fifth Annual Meeting of Spanish Experts 2023.肺炎中的热点问题。2023 年第五届西班牙专家年会的反思。
Rev Esp Quimioter. 2024 Jun;37(3):221-251. doi: 10.37201/req/018.2024. Epub 2024 Mar 4.
9
In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime/Avibactam-Susceptible and Resistant KPC-Producing Clinical Isolates.体外评估增加阿维巴坦浓度对头孢他啶针对产KPC的头孢他啶/阿维巴坦敏感和耐药临床分离株活性的影响。
Antibiotics (Basel). 2023 Dec 7;12(12):1707. doi: 10.3390/antibiotics12121707.
10
Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory.临床实验室中新型β-内酰胺类及β-内酰胺类联合制剂的检测方法
Antibiotics (Basel). 2023 Dec 5;12(12):1700. doi: 10.3390/antibiotics12121700.
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.
耐碳青霉烯类肺炎克雷伯菌感染治疗期间因质粒介导的突变导致头孢他啶-阿维巴坦耐药的出现
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02097-16. Print 2017 Mar.
4
Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.头孢他啶-阿维巴坦作为耐碳青霉烯类微生物所致感染的挽救治疗药物
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01964-16. Print 2017 Feb.
5
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.耐碳青霉烯类肠杆菌科细菌感染患者的临床结局、药物毒性及头孢他啶-阿维巴坦耐药性的出现
Clin Infect Dis. 2016 Dec 15;63(12):1615-1618. doi: 10.1093/cid/ciw636. Epub 2016 Sep 13.
6
In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase.携带KPC-3碳青霉烯酶的肠杆菌科细菌对头孢他啶-阿维巴坦耐药性的体外筛选
Antimicrob Agents Chemother. 2015 Sep;59(9):5324-30. doi: 10.1128/AAC.00678-15. Epub 2015 Jun 22.
7
Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop.头孢他啶/阿维巴坦对含KPC和SHVβ-内酰胺酶且Ω环有单个氨基酸取代的大肠杆菌同基因菌株的活性。
J Antimicrob Chemother. 2015 Aug;70(8):2279-86. doi: 10.1093/jac/dkv094. Epub 2015 May 8.
8
Treating infections caused by carbapenemase-producing Enterobacteriaceae.治疗产碳青霉烯酶肠杆菌科细菌感染。
Clin Microbiol Infect. 2014 Sep;20(9):862-72. doi: 10.1111/1469-0691.12697. Epub 2014 Jul 12.
9
Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.美罗培南在呼吸机相关性肺炎患者中3小时输注给药或静脉推注给药后的药效学比较。
Antimicrob Agents Chemother. 2005 Apr;49(4):1337-9. doi: 10.1128/AAC.49.4.1337-1339.2005.